| Previous Close | 0.0850 |
| Open | 0.0850 |
| Bid | 0.0850 x 0 |
| Ask | 0.0900 x 0 |
| Day's Range | 0.0850 - 0.0900 |
| 52 Week Range | 0.0250 - 0.3350 |
| Volume | 173,000 |
| Avg. Volume | 1,049,090 |
| Market Cap | 8.808M |
| Beta (5Y Monthly) | -4.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0120 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NESS-ZIONA, Israel, June 29, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, would like to provide an update on its previously announced brokered private placement of up to 58,823,530 units of the Company with minimum gross proceeds of $2,000,000 (the "Offering"), with M Partners Inc. as Lead Agent. Further details of the Offering are included in the Company’s press release from May 26, 2020. Net proceeds from the Offering will be used by the Company for continued pre-clinical research supporting development of the Company’s pipeline including a COVID-19 vaccine candidate, oncology and other infectious disease immunotherapies, as well as for general corporate purposes.
NESS-ZIONA, Israel, May 26, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that it has engaged M Partners Inc. (the "Agent") as lead agent and sole bookrunner to sell, by way of private placement, on a commercially reasonable efforts basis, up to 35,294,118 units ("Units") of the Company at a price of $0.085 per Unit to for aggregate gross proceeds of up to $3,000,000 (the “Offering”), subject to the Company’s receipt of minimum gross proceeds of $2,000,000 or 23,529,412 units of the Company. Each Unit will consist of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant").
NESS-ZIONA, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce the signing of a collaboration agreement between the Company and The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center (the “Tel Aviv Medical Center”) to advance the Company’s research program to develop a potential peptide vaccine against COVID-19. This agreement provides Vaxil with vital access to Tel Aviv Medical Center’s research resources including their unique bank of biological samples and its advanced research infrastructure.
NESS-ZIONA, Israel, April 28, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that the Company’s annual financial statements and management discussion and analysis for the year ended December 31, 2019 are now available to download on the Company's website at www.vaxil-bio.com/ and on Sedar at www.sedar.com. The Company ended the year with cash on hand of $83 thousand.
NESS-ZIONA, ISRAEL / ACCESSWIRE / April 21, 2020 / VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE:VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, today announced that it will be presenting at the Planet MicroCap Showcase 2020 on Wednesday, April 22, 2020 at 07:40 AM EST. Mr. David Goren (Chairman and CEO of Vaxil) will be hosting the presentation and answering questions from investors.
NESS-ZIONA, Israel, April 13, 2020 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated at 8:30 AM, April 13th. VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to share the results of our first preclinical experiment whose purpose was to test the immune response of our COVID-19 vaccine candidate.
NESS-ZIONA, Israel, April 13, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to share the results of our first preclinical experiment whose purpose was to test the immune response of our COVID-19 vaccine candidate. Dr. Mordechai Applebaum, PhD, Vaxil’s head of Research and Development, conducted and validated this experiment at the Company’s laboratory in Nes Ziona, Israel, over the last six weeks.
NESS-ZIONA, Israel, March 27, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to provide a update of its COVID-19 research program and other updates. In February 2020 we announced that we believed that we had successfully identified a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”).
NESS-ZIONA, ISRAEL, March 18, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that it has moved its website to a new domain – www.vaxil-bio.com. The Company is in the process of updating the website with specific information about our COVID-19 research program with respect of the potential vaccine. The Company also announces that since our recent press release dated March 15, 2020, a further, $70,000 (“Warrant Proceeds”) has been received from the exercise of 700,000 previously issued (January 2018) warrants, having an exercise price of $0.10 per warrant.
NESS-ZIONA, Israel, March 16, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that it has experienced technical issues with its website and is working to restore access to it in the coming days. The Company also announces that since our recent press release dated March 10, 2020, a further, $354,000 (“Warrant Proceeds”) has been received from the exercise of 3,540,000 warrants, having an exercise price of $0.10 per warrant, that were previously issued in January 2018.
Vaxil Bio Ltd. (V.VXL) hit a new 52-week high of 30 cents Friay. No news announcements today Arbor ...
Vaxil Bio Ltd. (V.VXL) hit a new 52-week high of 27 cents Thursday. No news announcements today WestBond ...
NESS-ZIONA, Israel, March 10, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that it has submitted a new patent application for its anti-infective vaccines platform as a result of our recently announced COVID19 candidate discovery. Vaxil has applied for a US patent (U.S 62/987,310) on a coronavirus vaccine that is intended to provide broad patent protection for novel vaccines, pharmaceutical compositions and methods of treating and preventing an infectious disease as well as methods for producing a peptide vaccine against coronaviruses.
NESS-ZIONA, Israel, March 04, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that, subject to receipt of final TSX Venture Exchange (“Exchange”) approval, it has closed on $36,000 (“Convertible Debenture Proceeds”) of convertible debentures from third parties (see press release of February 21, 2020) and $95,000 (“Debenture Proceeds”) of non-convertible debentures to certain insiders (“Debentures”). The Debentures bear an annual interest rate of 10% (“Debenture Interest”).
NESS-ZIONA, Israel, Feb. 21, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech focused on cancer and infectious diseases, announces that further to its press release from January 28, 2020 in connection with the Company’s convertible debt financing (the “Initial Press Release”), and following the press releases from February 13, 2020 and February 18, 2020 (the “Recent Press Releases”) regarding the possible identification of a Corona Virus Vaccine, the Company will continue to pursue its convertible debt financing but with the following amended terms (the “Amendments”). The Company will be issuing convertible debentures (the “Offering”) with a face value of $1,000 (“Principal”) and bearing an annual interest rate (“Interest”) of 10% (“Convertible Debentures”) for gross proceeds of up to $200,000 (“Proceeds”).
NESS-ZIONA, Israel, Feb. 18, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to provide further update to the Company’s press release dated February 13, 2020 on the possible identification of a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”). The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil’s proprietary VaxHitTM bioinformatics platform.
VANCOUVER , Feb. 14, 2020 /CNW/ - The following issues have been halted by IIROC: Company: Vaxil Bio Ltd. TSX-Venture Symbol: VXL (All Issues) Reason: Pending Company Contact Halt Time (ET): 9:43 AM IIROC ...
NESS-ZIONA, Israel, Feb. 13, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that it has completed in silico analyses and believes that it has successfully identified a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”). The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil’s proprietary VaxHit™ bioinformatics platform.
VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), announces that at the Company's Annual and Special General Meeting, held on November 4, 2019 in Toronto, all resolutions were duly passed by shareholders. Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases.
NESS-ZIONA, Israel, Sept. 10, 2019 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech focused on cancer and infectious diseases, is pleased to announce that the Company intends to complete a non-brokered private placement of up to 25,000,000 common shares at a price of CDN$0.04 per share for gross proceeds of up to CDN$750,000 (the “Offering”). The Offering is directed to all existing shareholders (including directors, officers and other insiders of the Company) as well as other Canadian and international investors. Closing of the Offering, which is at the discretion of the Company, is expected to be on or about September 30, 2019 and is subject to certain conditions including receipt of all necessary regulatory approvals, including approval of the TSX Venture Exchange.
NESS-ZIONA, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative immunotherapy biotech focused on cancer and infectious diseases, is pleased to announce that it has appointed Mr. David Goren, the Company’s Chief Executive Officer as its Chairman, replacing Mr. Isaac Maresky, who continues to serve on the Company’s board of directors. Mr. Goren stated: "I am very excited about this appointment as the Company moves into this next exciting phase.
NESS-ZIONA, Israel, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Vaxil Bio Ltd (TSX VENTURE: VXL), a biotech company focusing on innovative immunotherapy treatments for cancer and infectious diseases, announced today that it has entered into an exclusive worldwide license agreement for the development and commercialization of a targeted cancer therapy with BGN Technologies, the technology transfer company of Ben-Gurion University (BGU) of the Negev. Vaxil has found great interest in the P-Esbp polymer-based macromolecule invented by Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology, Prof. Gonen Ashkenazy of the Department of Chemistry and their joint PhD student Yosi Shamay all from BGU.